Prelude Capital Management, LLC Biogen Inc. Call Options Transaction History

Prelude Capital Management, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $116,814 - $161,076	-600 Reduced 26.09%	1,700 $454,000
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $168,786 - $200,718	-900 Reduced 28.13%	2,300 $469,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $310,032 - $390,624	1,600 Added 100.0%	3,200 $674,000
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $134,352 - $172,662	600 Added 60.0%	1,600 $384,000
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $1.4 Million - $2.24 Million	-5,400 Reduced 84.38%	1,000 $294,000
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $1.31 Million - $1.54 Million	5,400 Added 540.0%	6,400 $1.79 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $189,008 - $284,504	800 Added 400.0%	1,000 $245,000
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $3.02 Million - $3.49 Million	-11,400 Reduced 98.28%	200 $57,000
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $1.29 Million - $1.64 Million	4,800 Added 70.59%	11,600 $3.67 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $88,024 - $121,628	400 Added 6.25%	6,800 $2.02 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $241,219 - $265,892	-1,100 Reduced 14.67%	6,400 $1.5 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $1.63 Million - $2.54 Million	7,500 New	7,500 $1.77 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.